- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2016
- Public Summary Document (PSD) November 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2016 PBAC Meeting - Word
Blinatumomab – November 2016
Blinatumomab: Injection 38.5 microgram [1 vial] and inert substance solution [10 mL vial]; Blincyto®
Last updated
26 April 2017